Conclusions: KZR-616 up to 45 mg was well tolerated in HV and demonstrated consistent PK and PD. Selective immunoproteasome inhibition did not induce hematologic or constitutional toxicities associated with bortezomib. Candidate dose levels were identified to explore safety, tolerability and efficacy in patients with SLE and LN in an ongoing Phase 1b/2 study.

Disclosure of Interest: J. Lickliter: None declared, D. Bomba Employee of: Kezar Life Sciences, J. Anderl: None declared, A. Fan: None declared, C. Krik: None declared, J. Wang: None declared

AB0510 IMPROVING KNOWLEDGE OF SLE DISEASE FLARES AND TREATMENT OPTIONS AMONG RHEUMATOLOGISTS AND PRIMARY CARE PROVIDERS: EFFECT OF AN ONLINE EDUCATIONAL INTERVENTION

E. Jackson, D. Blatthenwick, K. Badal. Medscape Education, New York, USA

Background: With a significantly higher mortality in patients affected by systemic lupus erythematosus (SLE) developing chronic damage, prevention is a major goal in management. Flares are a common feature throughout the course of SLE and can result in organ damage. As a result, clinician knowledge on how to prevent, recognise, and treat flares is crucial.

Objectives: Determine whether an online educational intervention could effectively address a knowledge gap and an underlying educational need in the areas of SLE disease management among rheumatologists and primary care providers (PCPs).

Methods: An online educational intervention focusing on SLE disease management was made available online, intended for rheumatologists and PCPs who treat patients with SLE. The intervention consisted of a 30 min video presentation by a recognised expert in the treatment of SLE. Synchronised slides supported the presentation. The educational impact was assessed by comparing participants’ responses to 3 repeated-pair, multiple-choice pre- and post-intervention questions. The impact on self-reported confidence was also assessed through a 5-point Likert-scale question. Data were collected from 9/28/2017 through 11/29/2017. Statistical analysis included a paired 2-tailed t-test comparing mean pre-intervention and post-intervention scores. McNemar’s χ² statistic for measuring changes in responses to individual questions, and Cramer’s V to determine the overall impact of the intervention.

Results: Analysis of pre- versus post-intervention responses demonstrated a significant (p<0.05) improvement in overall knowledge in both rheumatologists (79% to 87%, n=118) and PCPs (61% to 73%, n=253). The overall impact of the intervention was similar in both groups (V=0.106 for rheumatologists and V=0.123 for PCPs). This intervention resulted in increased knowledge surrounding several specific areas of SLE, such as pathophysiology, relationship between disease activity and organ damage, and selection of SLE therapies (see table 1).

Abstract AB0510 – Table 1

<table>
<thead>
<tr>
<th>Topic area</th>
<th>Rheumatologists (n=118)</th>
<th>PCPs (n=253)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathophysiology</td>
<td>9% (75% to 84%, p=0.106)</td>
<td>23% (40% to 63%, p&lt;0.05)</td>
</tr>
<tr>
<td>Relationship between disease activity and organ damage</td>
<td>8% (84% to 92%, p=0.05)</td>
<td>5% (70% to 75%, p&lt;0.05)</td>
</tr>
<tr>
<td>Treatment selection</td>
<td>7% (79% to 86%, p=0.173)</td>
<td>6% (74% to 80%, p=0.093)</td>
</tr>
</tbody>
</table>

The intervention resulted in a 4% shift in self-reported confidence in addressing flare symptoms among rheumatologists, and a 26% shift among PCPs.

Conclusions: Participation in an online video educational intervention with synchronised slides was associated with significant overall improvement in knowledge levels of rheumatologists and PCPs in several important aspects of SLE management. Based on assessment of residual gaps, future directions for education should be tailored to specific learner groups including case-based reinforcement of knowledge and competence among rheumatologists, and additional foundational education for PCPs in the areas of pathophysiology and disease progression.

REFERENCES:

AB0511 THE EFFECT OF MILNACIPRAN ON FATIGUE IN A CLINICALLY STABLE LUPUS COHORT

E.P. Katsanos1, F. Dong2, I. Moldovan3, 1Internal Medicine, 2Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona; 3Internal Medicine, Loma Linda University, Loma Linda, USA

Background: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease impacting the physical wellbeing and health related quality of life (HRQOL) of patients. Fatigue occurs in up to 90% of SLE patients and affects their HRQOL. The purpose of this pilot study is to determine the effect of milnacipran, a norepinephrine and serotonin reuptake inhibitor used to treat fibromyalgia, on fatigue in clinically stable SLE patients with widespread pain (WSP).

To date, no clinical trials have demonstrated efficacy for the primary treatment of fatigue and WSP in adult SLE patients.

Objectives: The objective is to determine the effect of milnacipran on fatigue in a clinically stable lupus cohort.

Methods: SLE patients, 18 years and older, with fatigue, WSP and on more than 4 weeks of stable therapy were recruited for a 15 week prospective, double-blind, placebo-controlled study. Patients were randomised at a 1:1 ratio to receive 14 weeks of milnacipran 50–100 mg twice a day or placebo. Disease activity was measured by the Systemic Lupus Erythematosus Disease Activity Index (SLE-DAI). Measurements of fatigue, pain and a patient’s general impression of change from baseline were assessed at baseline and week 14 using the Fatigue Severity Scale (FSS), the Short-Form McGill Pain Questionnaire (SF-MPQ)2, and the Patient’s Global Impression of Change (PGIC) respectively.

Results: A total of 14 patients were included in the final analysis with seven patients in each group. Upon entry and throughout this study, both groups had low disease activity (mean SLEDAI =3.5 at week 0 and week 14). Fatigue as measured by FSS in the intervention group improved from 5.70 at week 0 to 5.14 at week 14 and improved in the placebo group from 5.90 to 5.59 respectively (Δ=0.56, 0.31 for the intervention and placebo group, respectively, p=0.70). Pain as measured by the SF-MPO showed improvement in the treatment group from 20.80 at week 0 to 18.80 at week 14, and in the placebo group from 15.40 to 13.2 respectively (Δ=2.00, 2.20 for the intervention and placebo group, respectively, p=0.97). The patient’s Global impression of change was greater in the intervention group than the placebo group (0.67 vs 0.49, p=0.21).

Conclusions: Although results were not significantly different in this pilot study, improvement in fatigue and the patient’s impression of global change appeared to be greater in the intervention group than the placebo group even though lupus activity remained low in both groups and the difference in pain between the two groups was nearly identical. Therefore, milnacipran may improve fatigue independently of disease activity and pain in lupus patients. Future randomised controlled trials of the drugs effect with larger cohorts are needed to confirm these findings.

REFERENCES:

Acknowledgements: Kendall Boyd, PhD, Loma Linda University Allergan/Forest Laboratories

Disclosure of Interest: E. Katsanos Grant/research support from: Allergan/Forest Laboratories, F. Dong: None declared, I. Moldovan: None declared

AB0512 OCCURRENCE AND CONSEQUENCES OF ANTI-DRG ANTIIBODIES TO RITUXIMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS

F. Faustini1, I. Parodis2, N. Dunn3, M. Ryner2, A. Fogdell-Hahn2, I. Gunnarsson1, 1Medicine, Unit of Rheumatology, 2Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Background: Anti-drug antibodies (ADA) to rituximab (RTX) have been reported to a limited extent in rheumatoid arthritis (RA, 4%–11%) and in multiple sclerosis (MS, 26%–37%), in the latter being associated with incomplete B-cell depletion. In SLE, data on the clinical significance of ADA are lacking.

Objectives: To define the frequency and consequences of ADA to RTX in a SLE population by setting a disease specific threshold using a sensitive ADA method.
Methods: SLE patients fulfilling the 1982 ACR classification criteria who received RTX treatment at the Karolinska University Hospital during the years 2001–2015 were included. Stored serum samples obtained prior to and after six months from initiation of treatment were analysed for the detection of ADA using a GSK-developed and validated electrochemiluminescence assay. Disease specific screening and confirmation cut-point for SLE samples (1.44 AU/mL and 29% respectively) were used. Clinical and laboratory data were retrieved from electronic medical charts. SLE activity was measured using SLE damage activity index 2000 (SLEDAI-2K).

We defined treatment response according to the SLE responder index (SRI).2

Results: Thirty-eight patients (89.5% females, median age 35.0 years; IQR: 27.7–55.0) were included in this retrospective analysis. The median disease duration was 6.2 years (IQR: 2.1–11.6) and the baseline median SLEDAI-2K was 6.9 (IQR: 7.0–16.5). The indications for RTX were active lupus nephritis (65.8%), CNS involvement (10.5%), arthritis (13.2%), haematological manifestations (7.9%), or mucocutaneous involvement (2.6%). Twenty-six patients (68.4%) received RTX according to the lymphoma regimen (375 mg/m² at day 1, 7, 14, 28) while 12 (31.6%) according to the arthritis regimen (2 infusions at a dose of 1 g, 14 days apart). Intraartenicular corticosteroids and cyclophosphamide were given in 65.8% and 63.2% of the patients, respectively.

ADA were detected in 18 patient samples (47.4%) at follow-up and stratified into reactive samples (confirmed positive but with a titer <2 AU/mL; n=3), low positive (2–10 AU/mL; n=6), medium positive (11–50 AU/mL; n=4), and high positive (>51 AU/mL; n=5). We found no association between the occurrence of ADA and either SRI response (p=0.26, Fisher exact test) nor the concomitant use of high dose IV 6-methylprednisolone (p=0.56, c² test) or IV cyclophosphamide (p=0.11, c² test). At follow-up, patients positive for ADA had higher levels of CD19+ B-cells (median: 0.03 × 10^9 cells/L; IQR: 0.01–0.13) compared to negative patients (median: 0.01 × 10^9 cells/L; IQR: 0.005–0.01; p=0.007, Mann-Whitney test).

Conclusions: ADA to RTX in SLE are more frequent than in RA and MS and occur irrespective of treatment response and cotreatments, but are associated with higher counts of CD19+B cells at follow-up. Such finding could reflect either incomplete B-cell depletion in ADA positive patients, or earlier repopulation. Further studies should address the relation between ADA titers and clinical outcomes as well as immunological consequences.

REFERENCES:

Disclosure of Interest: None declared